Ultimovacs ASA | MedPath

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

Ultimovacs ASA Provides Update on Clinical Trials and Financial Strategy

7 months ago

• Ultimovacs ASA reported active enrollment in the DVO trial for BRCA-negative ovarian cancer, with results expected in the first half of 2025. • The company halted recruitment for the LV trial in non-small cell lung cancer due to slow enrollment, with results anticipated in early 2025. • Ultimovacs is advancing a novel drug conjugation technology platform, with updates slated for the end of 2024, aiming to broaden its vaccine pipeline. • Financial strategies, including downsizing, have extended the company’s cash runway through the first quarter of 2026.

Ultimovacs Announces Q3 2024 Results and Strategic Update

7 months ago

• Ultimovacs extends cash runway through Q1 2026 via cash preservation initiatives implemented during the second and third quarters of 2024. • Phase II FOCUS trial in head and neck cancer did not meet the primary endpoint of improved progression-free survival, with no overall survival improvement observed. • Patient enrollment in the LUNGVAC trial (non-small cell lung cancer) has been discontinued due to slow recruitment; readout expected in H1 2025. • DOVACC trial (ovarian cancer) continues enrollment, with 148 of 184 patients recruited; readout anticipated in the first half of 2025.

Ultimovacs' UV1 Fails to Improve Outcomes in Head and Neck Cancer Trial

7 months ago

• The Phase II FOCUS trial evaluating Ultimovacs' UV1 vaccine plus pembrolizumab in head and neck squamous cell carcinoma (HNSCC) did not meet its primary endpoint of improving progression-free survival. • Secondary endpoints, including overall survival, also did not demonstrate a clinical benefit with the addition of UV1 to pembrolizumab. • UV1 maintained a positive safety profile, consistent with previous studies, showing good tolerability and similar adverse events in both treatment arms. • The trial investigated UV1's efficacy as a first-line treatment for metastatic or second-line treatment for recurrent PD-L1 positive HNSCC.

Pembrolizumab Approved for Mesothelioma; Patritumab Deruxtecan Shows Promise in NSCLC

8 months ago

• FDA has expanded the approval of pembrolizumab (Keytruda) in combination with pemetrexed and cisplatin for previously untreated advanced/metastatic malignant pleural mesothelioma. • Patritumab deruxtecan demonstrated a statistically significant improvement in progression-free survival versus doublet chemotherapy in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. • A novel three-drug regimen yielded an 80% response rate in a small study of patients with advanced chronic myelogenous leukemia or high-risk acute myeloid leukemia.

Ultimovacs Discontinues Patient Recruitment in Phase II Lungvac Trial for NSCLC

8 months ago

• Ultimovacs ASA halts patient recruitment for the LUNGVAC trial due to slow enrollment attributed to evolving NSCLC treatment options. • The Phase II trial investigated UV1 cancer vaccine combined with checkpoint inhibitors (cemiplimab or pembrolizumab) as first-line NSCLC treatment. • Data from the 31 enrolled patients will be analyzed, with topline results expected in the first half of 2025. • Ultimovacs continues to advance UV1 in ovarian cancer through the DOVACC trial and explore a novel drug conjugation platform.

Ultimovacs' UV1 Shows Promise in Mesothelioma Subgroup Analysis at ESMO 2024

9 months ago

• Ultimovacs presented updated data from the Phase II NIPU trial of UV1 in combination with ipilimumab and nivolumab for mesothelioma at ESMO 2024. • The epithelioid subgroup, representing 70% of mesothelioma patients, showed a median PFS improvement of 5.5 months with UV1 combination therapy compared to 2.9 months with immunotherapy alone. • While the primary endpoint was not met, secondary endpoint analysis revealed a positive overall survival difference with UV1 treatment at the latest follow-up. • Ultimovacs plans to discuss these findings with key stakeholders to determine potential next steps for UV1 in addressing the unmet needs of mesothelioma patients.